- Home
- TCBIO vs SNN Comparison
TCBIO vs SNN Comparison
Compare TCBIO & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
TCBIO
Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B
Current Price
Company Overview
Basic Information| Metric | TCBIO | SNN |
|---|---|---|
| Founded | N/A | 1856 |
| Country | United States | United Kingdom |
| Employees | 1818 | N/A |
| Industry | Major Banks | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 13.9B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | TCBIO | SNN |
|---|---|---|
| Price | $20.52 | $33.01 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $32.83 |
| AVG Volume (30 Days) | N/A | ★ 503.7K |
| Earning Date | N/A | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | N/A | ★ 59.91 |
| EPS | N/A | ★ 0.56 |
| Revenue | N/A | ★ $5,944,000,000.00 |
| Revenue This Year | N/A | $7.71 |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | ★ N/A | $28.52 |
| Revenue Growth | N/A | ★ 5.35 |
| 52 Week Low | N/A | $23.69 |
| 52 Week High | N/A | $38.79 |
Technical Indicators
Market Signals| Indicator | TCBIO | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 48.64 |
| Support Level | $20.58 | $32.66 |
| Resistance Level | $20.97 | $33.23 |
| Average True Range (ATR) | 0.21 | 0.41 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 20.97 | 51.35 |
Price Performance
Historical ComparisonAbout TCBIO Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.